Business
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of Directors LEXINGTON, Mass. and
About this update from Uniqure N.v.
[{"type":"text","content":"Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of Directors\nLEXINGTON, Mass. and AMSTERDAM, Aug. 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Ricardo Dolmetsch, Ph.D., as President, Research and Development, effective September 14, 2020. Dr. Dolmetsch will succeed Sander van Deventer, M.D., Ph.D, Executive Vice President, Research and Product Development. Robert Gut, M.D., Ph.D., will move from his role as Chief Medical Officer after a transition period following the start of Dr. Dolmetsch’s employment, and the Company plans for Dr. Gut to continue to serve on the Board of Directors.\n\n \n \n \n \n \n \n \n \n \n \n \n Ricardo Dolmetsch, Ph.D. announced as President, Research & Development at uniQure\n \n \n \n \n \n \n \n \n\n “I am thrilled to welcome Ricardo to the uniQure leadership team at this exciting time for the Company as we endeavor to aggressively advance our therapies for Huntington’s disease and other diseases and expand our pipeline of potentially transformative therapies,” stated Matt Kapusta, chief executive officer of uniQure. “Ricardo’s unwavering passion for genetically-defined diseases, deep experience with gene therapy and strong track record of successfully building a rich pipeline of preclinical and clinical-stage candidates make him an ideal successor to lead uniQure’s R&D operations at this moment in our history.” “This is an extraordinary time to join uniQure,” said Dr. Dolmetsch. “I was particularly attracted to the talented team of innovators that are focused on the singular mission of transforming patient lives. Not only does the company have a compelling track record of innovation but I believe it has exceptional potential with an industry-leading manufacturing and technology platform” said Dr. Dolmetsch. “Matt and the team share my commitment to developing treatments for patients with serious diseases and unmet medical needs. I’m very excited to be joining a world-class organization working toward the common goal of delivering gene therapies to patients around the world living with CNS and rare liver-directed disorders.” Dr. Dolmetsch joins uniQure from Novartis Institutes ...